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Abstract:  
Interleukin-7 receptor alpha (IL-7RA) is among the top listed candidate genes 
influencing the risk to develop multiple sclerosis (MS), an inflammatory demyelinating 
disease of the central nervous system. Soluble IL-7RA (sIL-7RA) protein and mRNA levels 
vary among the four common IL7RA haplotypes. Here we show and confirm that protective 
haplotype carriers have three times lower sIL-7RA serum levels than the other three 
haplotypes. High sIL-7RA concentrations significantly decrease interleukin-7-(IL-7) mediated 
STAT5 phosphorylation in CD4+ T cells. Transcriptome analysis of unstimulated and 
stimulated CD4+ T cells of MS patients carrying the different IL7RA haplotypes revealed 
complex and overlapping patterns in genes participating in cytokine signaling networks, 
apoptosis, cell cycle progression and cell differentiation. Our findings indicate that genetic 
variants of IL7RA result in haplotype-associated differential responsiveness to immunologic 
stimuli that influence MS susceptibility not exclusively by varying levels of sIL-7RA. 
Keywords: interleukin-7 receptor; polymorphism; multiple sclerosis
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Introduction 
 Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central 
nervous system (CNS). It affects mainly adults between 20 and 40 years of age 1. The 
etiology of MS is still incompletely understood, but both a complex genetic trait and 
environmental factors contribute to disease expression 2. At the level of individual genes the 
most important contribution to genetic risk stems from alleles in the human leukocyte antigen 
(HLA) class two region, namely the DR15 haplotype 3. Genome-wide association studies 
(GWAS) have discovered until today more than 50 common genetic variants, single 
nucleotide polymorphisms (SNP), that contribute to MS susceptibility 4,5, and it is expected 
that additional ones will be discovered in the near future. SNPs in the genomic region coding 
for the IL-7RA were the second set of confirmed MS risk alleles 6–8.  
 Among the IL7RA SNPs the nonsynonymous SNP rs6897932 located in exon 6 in the 
IL7RA gene shows the strongest association with MS 7,8. Several functional studies 
demonstrated that the risk “C” allele leads to an increased skipping of exon 6 resulting in a 
decreased ratio of full length- to soluble IL-7RA-encoding mRNA and an increased amount of 
sIL-7RA (H6)7,9,10. While this was repeatedly shown it remains an open question why only 
one out of three haplotypes comprising rs6897932 is positively associated with MS. Four 
SNPs, rs1494555, rs6897932, rs987107 and rs987106, are sufficient to tag the four main  
haplotypes that arise from the IL7RA gene locus (Figure 1) 7. Haplotype 1 is also referred to 
as the “risk” haplotype, because it is more prominent in MS patients compared to healthy 
donors (HD), whereas the opposite effect has been observed for haplotype 3, which has 
therefore been termed “protective” haplotype.  
 Regarding the functional effects of IL7RA haplotypes beyond altered sIL-7RA levels 
previous studies have shown differences between haplotype 2 and non-haplotype 2 carriers 
with respect to the frequency of recent thymic emigrants 11 and response of CD4+ 
lymphocytes to interferon beta 12. The functional effects on T cell stimulation of haplotype 2, 
which has not been found to related to MS risk, is thought to arise from differences in the 
genomic sequences within the promoter region of the IL7RA locus, which are also tagged by 
the SNPs used to define haplotypes. 
 In the context of MS and autoimmune diseases IL-7-mediated signaling likely acts 
through its involvement in lymphocyte development and/or homeostasis, but this may not be 
the only mechanism. IL-7 signaling through the IL-7R is indispensable for the development of 
human T lymphocytes 13 as demonstrated by the X-linked severe combined 
immunodeficiency (XSCID) phenotype of patients carrying a defect in the IL7RA. Given the 
central role of T cells in MS and other autoimmune diseases it is therefore reasonable to 
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assume that IL-7/IL-7R interactions are functionally involved in their pathogenesis, and it is 
interesting that not only SNPs in IL7RA, but also in the cytokine IL-7 are associated with MS 
14. The IL-7RA is mainly expressed by cells of the lymphoid lineage, but also by dendritic 
cells and monocytes 15,16. IL-7, is produced by non-hematopoietic stromal- and epithelial 
cells, but to lesser amounts also by dendritic cells (DC) 17. Binding of IL-7 leads to 
dimerization of the IL-7RA chain and the so-called common γ chain (γc), which then form the 
high affinity IL-7R 18. IL-7R shares its α chain with the thymic stromal lymphopoietin (TSLP) 
receptor, and the common γ chain with the receptors for IL-2, IL-4, IL-9, IL-15 and IL-21 19. IL-
7R-mediated signaling activates the JAK/STAT and PI3K/AKT signaling pathways 15,16. The 
homeostasis of naïve T lymphocytes is regulated by TCR and self-peptide MHC contact and 
the availability of pro-survival cytokines such as IL-7 16,18. Upon ligand engagement activated- 
as well as IL-7-stimulated T lymphocytes down-regulate the IL-7R, and since IL-7 is 
produced at relatively stable, but low levels by the abovementioned stromal cells, more IL-7 
is then available for naïve and memory T lymphocytes with the result that diverse repertoires 
of naïve and antigen-experienced memory T cell populations are maintained 15. 
 IL-7 also plays a role in other autoimmune diseases such as rheumatoid arthritis (RA) 
where it has been shown that IL-7 serum and synovial fluid concentrations are elevated in 
comparison to healthy donors and in addition are correlated with disease activity 20. Hartgring 
and colleagues 21 were able to demonstrate in an in vitro model that recombinant sIL-7RA 
reduces IL-7-mediated proliferation and production of interferon gamma (IFN-γ) of PBMCs. 
Interestingly, anti-IL-7RA antibody treatment of either mice with collagen-induced arthritis 
(CIA) or experimental autoimmune encephalomyelitis (EAE), led to reduced disease 
severity22–24. The above data indicate that dysregulation of the IL-7/IL-7R system may 
contribute to disease pathogenesis and pathologic immune activation during autoimmune 
diseases. Its physiological roles include not only the functions in T lymphocyte generation 
and -homeostasis, but also coping with chronic viral infections 25.  
 Despite robust confirmation of the associations of IL7RA SNPs with MS, the 
understanding of the possible functional contributions of IL7RA risk-conferring alleles to MS 
pathogenesis is still incomplete. The goals of the present study were to characterize immune 
cells of MS patients carrying risk- or protective IL7RA alleles with respect to membrane- and 
sIL-7RA expression, to examine how the increased sIL-7RA serum concentrations in risk 
allele carriers impact on IL-7/IL-7R functions, and if transcriptional profiling in individuals 
carrying the various IL7RA haplotypes leads to additional insight into their potential functional 
contribution to MS. 
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Results 
Association of SNP rs6897932 with MS 
 First, we analyzed the IL7RA allele, genotype, and haplotype distribution in a cohort 
of Northern German, Caucasian MS patients (n=484) and healthy donors (HD) (n=310). Four 
tagging SNPs (rs1494555, rs6897932, rs987107 and rs987106) were used to identify the 
four common IL7RA haplotypes. Due to the small sample size we did not expect to reach 
statistical significance. Surprisingly, however, this was the case for SNP rs6897932 (Table 1). 
The dominant model fit best to our data and confirmed an increased MS susceptibility for 
homozygous carriers of the “C” allele of the SNP rs6897932 (p=0.03; OR=1.38 [95% 
confidence interval: 1.04 – 1.84]). No significant association with disease could be detected 
for the other three SNPs. However, the genotype frequencies in the Hamburg cohort were 
similar to previously published reports 7,26. As expected for a small cohort, no statistical 
significance was reached for the haplotype distribution (Table 2). 
mRNA- and Protein Expression Correlate with IL7RA Haplotype  
 Previous studies 9,10 demonstrated an influence of the IL7RA haplotype on the splicing 
resulting in an increased serum concentration of sIL-7RA. To determine whether or not we 
can confirm these effects, we analyzed the IL-7RA mRNA- as well as protein expression in 
haplotype 1-4-carrying homozygous MS patients. The relative expression of the full length 
(H20), the soluble isoform missing exon 6 (H6) and all common IL-7RA isoforms was 
determined by RT-PCR. Carriers of the protective haplotype had an increased ratio in the 
expression of membrane bound to soluble IL-7RA compared to carriers of the other 
haplotypes (Figure 2 A). In contrast and consistent with previous results risk allele carriers 
showed a significantly reduced ratio, i.e. a relative increase of the soluble isoform and a 
slight reduction of the full-length isoform (Supplementary Material, Figure S1). 
 We then examined the IL-7RA serum concentration of homozygous MS patients of 
the four common IL7RA haplotypes by ELISA. Analysis of sIL-7RA protein expression is in 
accordance with the gene expression analysis. Patients carrying the protective haplotype 
had three times lower sIL-7RA serum concentrations compared to carriers of the other three 
haplotypes (Figure 2 B). MS patients heterozygous for the SNP rs6897932 had intermediate 
sIL-7RA serum levels (Figure 2 B). Therefore, consistent with the reports of Hoe et al. 9 we 
demonstrate an allele dosage influence of SNP rs6897932 on the sIL-7RA serum 
concentration. 
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Altered IL-7RA Surface Expression on Natural Killer Cells in Relation to the IL7RA 
Haplotype  
 Next, we addressed if carriers of the risk- versus protective IL7RA haplotypes show 
differences in membrane expression of the receptors on different immune cells including 
CD4+ and CD8+ bulk T cells, the naïve- and memory populations of these two subsets, 
regulatory T cells, several subpopulations of dendritic cells, and the two main populations of 
natural killer cells (CD56dim and CD56bright). We hypothesized that the greatest differences 
might be observed between the risk- and the protective haplotypes because these varied 
most with respect to their putative effects on MS susceptibility. We found a significant, albeit 
small difference for CD56bright NK cells (Figure 3). Risk haplotype carriers showed 
significantly lower IL-7RA surface expression compared to carriers of the protective 
haplotype (p-value=0.014). While there were consistent trends towards lower IL-7RA 
membrane expression of several immune cell populations of risk haplotype carriers, e.g. in 
naïve CD4+ T cells and Tregs, these did not reach statistical significance (Supplementary 
Material, Figure S2). 
sIL-7RA Inhibits STAT5 Phosphorylation 
 Next, we questioned if the sIL-7RA levels interfere with T cell function by influencing 
the availability of cytokine for binding to the membrane-bound IL-7R and hence IL-7R-
mediated signaling. Previous studies have shown that sIL-7RA can bind IL-7 27,28. Although 
the affinity is lower 29,30 than that of the membrane-bound form, the soluble IL-7RA 
(concentrations in risk haplotype carriers 50-185 ng/ml) may be capable of influencing the 
availability of IL-7, due to the fact that it is available in the serum at an up to ninety thousand-
fold excess compared to the free cytokine IL-7 (levels 2-8 pg/ml). So far most studies used 
the recombinant IL-7RA (R&D, 306-IR-050) or sIL-7RA produced by WI26VA4 cells, which 
shed the IL-7RA upon IL-7 stimulation, to analyze the effect of sIL-7RA on IL-7 signaling. 
Because the H6 isoform, which misses exon 6, is the most common soluble IL-7RA isoform 
in human plasma, we decided not to use the full length (H20) or shed form of the IL-7RA, but 
express the soluble form lacking exon 6 and generated in excess in risk allele carriers. We 
established an IL-7RA (isoform H6)-secreting HEK cell line. Using this sIL-7RA (H6) we 
analyzed the effect of sIL-7RA on IL-7R-mediated STAT5 phosphorylation in human CD4+ T 
lymphocytes by flow cytometry. We observed clear differences between CD4+ T lymphocytes 
stimulated in absence or presence of sIL-7RA with IL-7 (Figure 4 A-D). The strongest effect 
was observed for CD4+ cells stimulated with 10 pg/mL IL-7 in presence of sIL-7RA (isoform 
H6), resulting in a 50% reduced STAT5 phosphorylation. According to our data the strength 
of the observed effect correlates with the ratio between IL-7 and the sIL-7RA (Figure 4 A-D). 
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These data suggest a functional relevance of the increased sIL-7RA concentrations in 
carriers of the risk haplotype.  
IL7RA Haplotype-Associated Gene Expression Patterns 
 The above data demonstrate that carriers of haplotype 1, 2 and 4 have increased sIL-
7RA serum levels due to differential splicing. Hence, it is remarkable that only haplotype 1 
carriers show an increased risk for MS. We therefore wanted to address next, if the IL7RA 
haplotypes differ in further aspects beside the sIL-7RA concentration. Since CD4+ T cells are 
particularly critical for MS 1, we performed global gene expression profiling of CD4+ T cells 
from MS patients that were homozygous for one of the three haplotypes (Hap1, Hap2, 
Hap3). Due to a lack of patients carrying haplotype 4, which is also the rarest of all four 
haplotypes, we were not able to include this haplotype in the gene expression analysis. 
Purified CD4+ T cells were analyzed unstimulated and after challenge with IL-7 to specifically 
address the IL-7/IL-7R system. Concentrations of IL-7 and sampling times were chosen 
based on pilot experiments monitoring BCL2 as major up-regulated gene following IL-7RA 
stimulation (not shown). The experimental design aimed at comparing gene expression 
profiles in carriers of the three haplotypes at basal level and more importantly also at 
examining haplotype-specific effects following IL-7RA stimulation.  
 Resting condition: Expression levels in unstimulated cells showed a trend towards 
haplotype-specific differences when a fraction of genes selected solely by the criteria of 
showing minimal intra-group variance was inspected with multidimensional scaling (843 
Ensembl gene IDs, Supplementary Material, Table S1 and Figure S3 A). Although no gene 
reached statistical significance applying the widely used multiple test correction (Benjamini-
Hochberg; two-group t-test as well as three-group F-tests) (Table 3, Supplementary Material, 
Table S1 and Figure S3 A) we noted that the gene list contains several spliceosomal RNAs 
and micro RNAs. This may indicate that the different haplotypes are associated with varying 
capacity to react to cytokine stimulus at the transcriptional level especially for the extent to 
which splicing occurs, but also at the translational level for an immediate response to stimuli  
 IL-7-stimulated condition: The treatment of purified CD4+ T cells with IL-7 induced a 
robust response with the majority of the most significantly responding genes being up-
regulated (203/225 genes, top 1% of significantly regulated genes corresponding to adjusted 
p-value ≤ 1.6 E-5, total gene number at 0.05 level 3276). When combining individual samples 
by stimulus irrespective of haplotype assignment, particularly strong effects were seen for 
BCL2, CISH, IRF4, CDK6, PPAP2A, CEACAM1, ENO1, PTGER2, SLC37A3, CTPS (all up-
regulated) and FAIM3, IL7R, GCNT4, ARHGAP9, SORL1, DPEP2, MPP7, TMEM71, 
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GIMAP2, ST6GALNAC2 (all down-regulated) (Table 4, Supplementary Material, Table S2 
and Figure S3 B). For some of these genes a direct link to the JAK/STAT pathway, which is 
employed as the IL-7/IL-7R signaling pathway, is already known or may be inferred from 
analysis of STAT5-occupied DNA sites (CISH, BCL2, CDK6, CEACAM1, CTPS, GCNT4, 
PPAP2A, PTGER2, ST6GALNAC2, MPP7) 31.  
 Analyzing individual responses considering the most stable signals for 
multidimensional scaling already showed grouping of individuals according to haplotypes 
(Figure 5 A). Of note, this grouping was obtained from an exploratory data analysis with 
unsupervised clustering, i.e. blind to haplotype assignment, and cannot be accounted for by 
SNP rs6897932 alone. Further inspection made clear that a considerable number of genes 
that changed in expression after IL-7 stimulus did not show concordant changes or differed in 
effect size between haplotypes (Supplementary Material, Table S3). Given the complex and 
overlapping participation of MS-associated genes in several signaling pathways we applied 
an unsupervised clustering technique (nonnegative matrix factorization, NMF) in order to 
extract haplotype-specific features from our high-dimensional gene expression data. NMF 
assigns weights to genes from a common input list according to their discriminatory power, 
which allows to distinguish a given group from the remaining ones and hereby creates group-
specific profiles (metagenes). 
 We considered genes showing robust IL-7 responses (adjusted p-value ≤ 0.05) in 
combination with differences in response between haplotypes (F test, p-value ≤ 0.05, 209 
genes, see Methods, Supplementary Material, Table S3) for NMF and observed a highly 
reproducible clustering of individuals as judged by the reported cophenetic coefficient 
(peaking at factorization rank k=3) almost independent of the applied algorithm 
(Supplementary Material, Figure S4 A-D). The IL-7 response signals from a combination of 
top-ranked metagene members clearly show an overlapping pattern of differential reactivity. 
We note that haplotype 1 and 2, both comprising the rs6897932 risk allele, differ in their 
response to a considerable amount (Figure 5 B, Supplementary Material, Table S3).  
 In order to assess whether the top metagene-contributing genes are related to a 
specific signaling pathway and biologically plausible in the context of IL-7/IL-7R signaling, we 
queried the Reactome database. IL7, IL7R, IL2RB, KRAS, IFNGR2, and SUMO1 all 
participate in cytokine signaling in immune system networks (Reactome ID 75790, Figure 5 
C) and sub-networks. Combining this information with interaction data from STRING 
(confidence score ≥ 0.7) identified even more genes from the input list to be associated with 
cytokine signaling. How and to which extent differential responses of those genes and 
potential additional partners might shape haplotype-associated responses is not clear, but it 
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appears that despite the limited sample size the obtained interconnections indeed relate to a 
genome-defined response pattern to immunologic stimuli. Of note, three cytokines and 
cytokine receptors, i.e. IL-7, IL-7R and IL-2R that have been associated with MS risk appear 
as metagenes in this pathway (Figure 5 C).  
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Discussion  
 IL-7 is a critical factor for regulating T lymphocyte development and -homeostasis 32. 
The IL-7/IL-7R system has been described to play a role in MS as well as in other 
autoimmune diseases such as type 1 diabetes, rheumatoid arthritis and inflammatory bowel 
disease 24,33,34. There is compelling evidence from animal models of these diseases that 
blocking of the IL-7RA leads to an amelioration of the disease course by modulating 
inflammatory processes 22–24,33,34. For MS, we and others 9 could demonstrate highly 
significant differences in the amount of sIL-7RA between the haplotypes. Carriers of the risk 
haplotype showed up to three times higher sIL-7RA serum concentrations compared to 
carriers of the protective haplotype. The observation, that sIL-7RA is capable of reducing IL-
7-mediated STAT5 phosphorylation in CD4+ T cells is in line with data of Crawley et al. 28, 
who demonstrated that sIL-7RA reduces IL-7-mediated signaling in CD8+ T cells, even 
though these authors did not use the sIL-7RA (H6), which is generated by differential splicing 
in MS risk haplotype carriers. Besides the JAK/STAT pathway, IL-7 also activates signaling 
pathways that influence cell metabolism as well as proliferative capacity 35. Hence, the risk 
haplotype could result in reduced lymphocyte proliferation due to an inhibitory effect of the 
elevated sIL-7RA levels on IL-7-mediated signaling. An alternative interpretation is that the 
vast excess of sIL-7RA may serve as a sink or reservoir of IL-7, which could be released 
under conditions of for example lowered pH, which may occur in a local inflammatory 
environment. These scenarios are not mutually exclusive but may rather be relevant in 
different contexts such as homeostatic versus immune-activating conditions. While our data 
do not exclude the latter hypothesis that increased sIL-7RA concentrations act immune-
activating rather than compromising homeostatic turnover, the inhibition of STAT5 signaling 
and reduction of proliferation by sIL-7RA 21 argue for the latter. 
 Autoimmunity involves breakdown of immune tolerance and among other factors an 
increased proliferation of autoreactive T lymphocytes. Thus, the increased sIL-7RA serum 
concentration and the reduced proliferation seem to contradict an increased risk of haplotype 
1 carriers for MS. However, the immunomodulatory capacity of the excess of sIL-7RA might 
increase MS susceptibility in an indirect way. A recent study by Pellegrini et al. 25 
demonstrated that IL-7 treatment reinvigorates the immune response and improves 
protection against chronic viral infections. Furthermore, treatment with recombinant IL-7 
promotes T cell recovery after allogeneic stem cell transplantation 36 and also supports the 
elimination of JC polyoma virus in patients with progressive multifocal leukoencephalopathy 
(PML), an opportunistic and often fatal infection of the brain in immunocompromised 
individuals (Sospedra et al., unpublished). One possibility is that the lower bioavailability of 
IL-7 in carriers of the risk haplotype caused by sIL-7RA sequestration of IL-7, increases the 
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susceptibility to viral infection. Since viral infections are known to precede MS relapses  and 
considering that EBV is the most important environmental risk factor of MS 37, the increased 
levels of sIL-7RA and lower IL-7 bioavailability may lead to an at least subtle compromise in 
controlling viral infections, which then indirectly might contribute to onset of MS and/or 
occurrence of relapses/perpetuation once it has begun. This is supported by recent findings 
that the MS risk-conferring SNP rs6897932 is among three SNPs that confer poor outcome in 
HIV infection 38. Another line of supporting evidence is the reduced expression of IL-7RA on 
CD56bright NK cells, and therefore possibly compromises in generating or maintaining this 
subset of NK cells. CD56bright NK cells are not only important for the control of 
latent/persistent viral infections 39, but also have immunoregulatory properties 40. CD56bright 
NK cells are reduced in numbers and compromised in function in MS patients 41, and 
treatment with the anti-CD25 monoclonal antibody daclizumab leads to significant expansion 
of CD56bright NK cells, resulting in a decrease of inflammatory disease activity and of MS 
relapses 40,42. 
 When considering the influence of single quantitative trait loci (QTLs) like the MS risk-
associated IL7RA SNP on a complex disease like MS they appear to contribute only in a very 
minor way to MS risk, and their disease association could only be detected by comparing 
large numbers of patients and controls 5. One therefore expects that such QTLs act in 
concert with others and influence functional pathways that translate into increased pro-
inflammatory cytokine secretion, T cell activation and other immune mechanisms that 
functionally contribute to a disease like MS. Since it is very difficult to dissect such 
interactions in genetically highly heterogeneous individuals, it is not surprising that with few 
exceptions 43 very little is known about the functional role of MS risk alleles. Also, one would 
not expect strong signals, e.g. with respect to an important aspect of immune function, in the 
context of common variants as this most likely would result in a readily observable 
phenotype. From a systems perspective however, it is conceivable, that even small 
differences in amount of sIL-7RA protein, bioavailability of IL-7 and/or transcriptional activity 
defined by IL7RA haplotypes shape the individual immune response and eventually sum up 
to discernible amounts. At the typical age of onset around 30 years, MS patients have 
undergone numerous immunologic challenges. It is therefore highly interesting to note that 
Lundström et al.44 find differences in IL-7 levels between rs6897932 genotypes in MS 
patients. Considering these aspects our data on the complex pattern of differential response 
in CD4+ T cells in IL7RA haplotype homozygous individuals are not too unexpected and 
suggest that MS individuals differ in their response to immunologic stimuli. The application of 
conservative statistical significance thresholds will in these instances tend to underestimate 
biologically relevant information.  
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 As presented above, among the top induced changes in gene expression following 
stimulation of CD4+ cells with IL-7 there were no major haplotype-specific differences. In 
brief, the signal given by IL-7/IL-7R affects regulation of apoptosis, cell cycle progression, 
and differentiation (up-regulation of CISH, BCL2, CDK6, CTPS, IRF4 and ENO1, down-
regulation of IL7R, FAIM3, GIMAP2, TMEM71). In addition, substantial remodeling of cell-cell 
and cell-substrate interactions, adhesive properties, and cellular skeleton is triggered 
(CEACAM1, SORL1, MPP7, ARHGAP9, ST6GALNAC2). Interestingly, genes involved in lipid 
uptake and metabolism also show considerable expression level changes (PTGER2, 
DPEP2). Of note, PPAP2A (phosphatidic acid phosphatase type 2A) exhibits high 
phosphatase activity toward FTY720 phosphate, the active form of the immunomodulating 
agent FTY720 (Fingolimod), which is an approved drug for the treatment of MS 45. Among the 
many affected genes the IL-7 response of a limited number of these differs between 
haplotypes and can be used to derive transcriptional signatures ('metagenes') indicating 
variable processing of cytokine signals. Interestingly, genes in the first-line response to 
pathogens are top metagene-defining features. These include among others IFNGR2, the 
receptor for probably the most important pro-inflammatory cytokine in several autoimmune 
diseases including MS, TLR2, which plays a fundamental role in pathogen recognition 
including also viruses like EBV, CX3CR1, a chemokine acting as a coreceptor for HIV-1, and 
ALOX5, a lipoxygenase gene family member, for which over-expression in MS, both in 
relapse and remission, was reported recently. The transcription factor XBP1, which regulates 
MHC class II genes, acts as viral transactivator and also responds to endoplasmatic 
reticulum stress, was placed among the top metagenes. The ability to respond to 
environmental stimuli is also defined by metabolic fitness and sensitivity to apoptosis of 
immune cells. Reflecting this, NDUFA2 and NDUFV2, which participate in mitochondrial 
electron transport chain assembly, came up in our network analysis. Interestingly, it has been 
proposed that mitochondrial proteins, and especially haplotypic variants, may also influence 
progression of viral diseases like AIDS 46. Of interest for a neurological disease like MS, 
compromise of mitochondrial function and metabolic compromise of neurons have been 
implicated in neurodegenerative processes 47. Although speculative at this point, the 
expression of IL-7RA in the central nervous system 48,49 may indicate that it exerts an 
influence not only in the immune system, but also in the brain.  
 On the basis of our findings, we hypothesize that the IL7RA risk haplotype increases 
the susceptibility for viral infection, thereby enhancing the risk for MS. However, MS is a 
disease with a complex genetic trait, in which the IL7RA is only one piece in the extending 
puzzle of MS genetics. It is most likely that the IL7RA acts in concert with other genes to 
trigger MS. Here we show that by combining genetic information, specific cytokine stimulus, 
gene expression-, and network analysis one can gain insight into the complex interactions of 
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sets of haplotype-specific metagenes and involved signaling pathways, which together 
suggest an influence of IL7RA haplotypes not only on immune mechanisms, but possibly 
also metabolic function and an involvement in neurodegenerative aspects of MS. This 
approach is promising in addressing the functional implications of individual polymorphisms 
with small effects found in many genome-wide association studies and expression 
quantitative trait loci studies on autoimmune diseases. 
14 
 
Methods 
Subject and Sample Collection 
 Patient material was collected from 484 MS patients (29.8% males, 70.2% female, 
with a mean age of 45 years and a mean EDSS of 3.3) and 310 healthy donors (50% male, 
50% female, with a mean age of 37 years) from the Hamburg cohort available at University 
Medical Center Hamburg-Eppendorf. Informed consent was obtained from all MS patients 
and healthy donors. All patients had a clinically defined MS according to McDonald criteria 50. 
Peripheral blood was collected in ETDA tubes (Sarstedt, Nümbrecht, Germany) and serum 
was collected in serum monocyvettes (Sarstedt, Nümbrecht, Germany). 
Cell Isolation 
 PBMCs were isolated by Ficoll (PAA, Pasching, Austria) gradient centrifugation, 
washed twice, resuspended in RPMI 1640 supplemented with 10% DMSO and 20% FCS 
and cryopreserved. CD4+ T cells were enriched from freshly isolated PBMCs by using the BD 
enrichment set DM (BD Biosciences, New Jersey, USA) following manufacturer’s protocol 
achieving a purity of at least 95%, verified by flow cytometry. 
Genotyping 
 Genomic DNA was isolated from whole blood. Cells were lysed (1.6 M sucrose, 5% 
v/V Triton X-100, 25 mM MgCl2 and 60 mM Tris-HCl pH 7.5), centrifuged (1950 g), the pellet 
resolved in H20 supplemented with proteinase K and 20% SDS, incubated over night at 
37°C, centrifuged (3000 g) and precipitated with NaCl (6 M). After centrifugation (3000 g), the 
DNA was washed with 100% and 70% ethanol. Four SNPs in the IL7RA gene (rs987106, 
rs987107, rs1494555, rs6897932) were analyzed using predesigned TaqMan probes 
(Applied Biosystems California, USA). The reaction was performed in an Applied Biosystems 
7900 Real-Time PCR system. 
Association Analysis 
 Genotype information was analyzed with Haploview 4.2 51 and PLINK v1.07 (Shaun 
Purcell; http://pngu.mgh.harvard.edu/purcell/plink/). None of the obtained genotype 
distributions did show significant deviation from Hardy-Weinberg equilibrium. 
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Gene Expression Analysis of Different IL-7RA Isoforms 
 RNA was isolated form PBMC-pellets using RNeasy kit (Qiagen, Hilden, Germany). 
cDNA synthesis was performed with Fermentas RevertAid H Minus first strand cDNA 
synthesis kit (Fermentas, St. Leon-Rot, Germany). Three pre-designed TaqMan (Applied 
Biosystems, California, USA) probes (HS_00902334_m1, HS_00904815_m1, 
Hs_00902337_m1) were used to monitor membrane bound (H20), the soluble (H6) IL-7RA 
isoform, and the total amount of IL-7RA encoding mRNA. The quantitative PCR reaction was 
performed in duplicates in an Applied Biosystems 7900 Real-Time PCR system. 
Quantification of sIL-7RA 
 IL-7RA serum concentrations were determined by sandwich ELISA with capture 
antibody (MAB306), detection antibody (BAF306), HRP-conjugated streptavidin (DY998) and 
substrate (DY997), all from R&D (Minnesota, USA). Serum samples were diluted 1/20 using 
PBS supplemented with 10% FCS. Microtiter plates were analyzed using a Perkin-Elmer 
(Massachusetts, USA) multilabel plate reader. 
Cell Surface Expression of IL-7RA on Immune Cell Populations 
 Quantification of IL-7RA surface expression was performed with frozen PBMCs using 
flow cytometry (LSRII, BD Biosciences, New Jersey, USA). In all stainings duplicates were 
eliminated. CD4+ and CD8+ T-cells subtypes were identified by labeling the cells with 
antibodies specific for CD4 (Caltag Laboratories), CD8 (BioLegend, San Diego, USA), CD27 
(BD Biosciences, New Jersey, USA), CD45RO (BioLegend, San Diego, USA) and CD127 
(Beckman and Coulter, Indianapolis, USA). IL-7RA expression on dendritic cells was 
analyzed by eliminating CD14 (BD Biosciences, New Jersey, USA) and CD19 (BD 
Biosciences, New Jersey, USA) positive cells and gating on CD1c, CD141 or CD303 (all from 
Miltenyi Biotec, Bergisch Gladbach, Germany) positive cells. Natural killer (NK) cells were 
subdivided into CD56dim and CD56bright by using antibodies specific for CD3 (eBioscience, 
San Diego, USA), CD16 (BioLegend, San Diego, USA), CD56 (eBioscience, San Diego, 
USA) and CD127 (BioLegend, San Diego, USA). Tregs were defined as CD3, CD4 and 
FoxP3 positive and CD25 high expressing cells. The following antibodies were used CD3 
(BD Biosciences, New Jersey, USA), CD4 and CD127 (BioLegend, San Diego, USA), CD25 
(eBioscience, San Diego, USA) and intracellular FoxP3 and FoxP3 staining buffer set 
(Miltenyi Biotec, Bergisch Gladbach, Germany). The stainings were performed according to 
manufacturers’ protocols. 
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Cloning and Stable Expression of Soluble IL-7RA 
 Human cDNA encoding the soluble IL-7RA (H6; AK301220) was amplified in two 
steps. First the regions encoded by exon 1-5 (forward-primer: 5´-
AATGACAATTCTAGGTACAACTTTTGGCATGGTTTTTTC; reverse-primer: 
CGATAGGCTTAATCCTGAGCTATTATTG) and 7-8 (forward-primer: 5´- CAATA 
ATAGCTCAGGATTAAGCCTATCG; reverse-primer: 5´-CTCACTTTTCTTGGT 
TTCTTACAAAGATGTTC) were amplified and in a second step the two constructs were 
combined and modified with EcoRI and XhoI binding-sites (forward-primer: 5´-
GTAGAATTCGCCTCCATGACAATTCTAGGTACAACTTTTGGCATGGTTTT, reverse-primer: 
5´-GACTCGAGCTCACTTTTCTTGGTTTCTTAC). The construct was cloned into pcDNA3.1 
(Invitrogen, California, USA) and transformed into E. coli strain Top10F-. 
Stable transfection of HEK293 cells was performed using Lipofectamine 2000 (Invitrogen, 
California, USA) according to the manufacturer’s protocol. In short: HEK cells with a density 
of approximately 80% were transfected with 3 µg linearised DNA and grown under selection 
conditions in DMEM (Invitrogen, California, USA) supplemented with 10% FCS and 0.8 
mg/ml G418 (PAA, Pasching, Austria). The efficiency of the transfected HEK cells to secrete 
IL-7RA was determined by ELISA (see above).  
STAT5 Phosphorylation  
 The phosphorylation state of STAT5 was measured by flow cytometry. Freshly 
isolated CD4+ T cells were pre-incubated for 2h at 37°C in RPMI 1640 Glutamax (PAA, 
Pasching, Austria) supplemented with 10% FCS and then stimulated with the as well pre-
incubated stimulus for 15 min. The following components were used for stimulation: IL-7 
(Sigma Aldrich, Missouri, USA), concentrated HEK-cell supernatant and concentrated 
supernatant of a HEK-cell line producing soluble IL-7RA. Directly after stimulation the cells 
were fixed and permeabilized by using Cytofix Buffer and 1x Perm Buffer III (both from BD 
Biosciences, New Jersey, USA).  Phospho-STAT5 (anti-STAT5-P (Y694), BD Biosciences, 
New Jersey, USA) was measured by flow cytometry. 
Transcriptome Analysis 
 Transcriptomes  from CD4+ T cells from patients with haplotype 1 (n=3), haplotype 2 
(n=2), and haplotype 3 (n=2)  were recorded using Affymetrix human gene array chips 
(GeneChip Human Gene 1.0 ST Array) hybridized at Transkriptomanalyselabor, University of 
Göttingen, Germany (tal@gwdg.de). In brief, RNA was isolated using the TRIzol® Reagent 
(Invitrogen) and checked for quantity, purity and integrity using the Agilent 2100 bioanalyzer 
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(Agilent Technologies). Microarray hybridization and data extraction was done according to 
the manufacturer's specifications.  
Raw microarray data were background corrected and normalized by applying robust multi-
chip average and quantile normalization. Processed probe expression values were 
condensed into Affymetrix transcript clusters and filtered for genes containing Entrez gene 
identifier. Differential expression was calculated via fitting a linear model with moderated t-
statistics to groups defined by haplotype, treatment, and combinations of haplotype and 
treatment. All calculations were done in R/Bioconductor 52. For initial exploratory data 
analysis, expression levels of unstimulated cells were inspected for genes (only autosomal 
location) that showed small median absolute deviation (lower third calculated per haplotype 
group) with a reasonable minimal expression (threshold set to 4.0). The resulting set 
corresponding to 843 Ensembl gene IDs was subjected to non-metric multidimensional 
scaling (Sammon's Non-Linear Mapping) and plotted. Haplotype specific effects were 
inspected in a similar way. For detailed analysis of haplotype-associated signatures we used 
genes showing robust response to IL-7 treatment in at least one of the haplotype groups 
(Benjamini-Hochberg adjusted p-value ≤ 0.05) which at the same time differed between 
haplotypes (F-test, p-value ≤ 0.05). Data with high intra group variation taken as median 
absolute deviation ≥ 0.5 were removed. Nonnegative matrix factorization (NMF) on the 
resulting 207 differentially responding genes with autosomal location as input (completed 
with data for IL-7 and IL-7RA) was used to extract subsets of haplotype-specific genes 53. In 
NMF, the gene expression levels are treated as matrix X consisting of N genes in M samples 
that is factorized according to X = W x H into a metagene matrix W and a metagene 
expression profile (meta experiment) matrix H. Columns of W hold the contribution of genes 
to a metagene, and columns of H describe the metagene composition corresponding to each 
sample. The optimal rank k (number of extracted basis components) was inferred from 
plotting the cophenetic correlation coefficient versus rank and was set to three. Initial tests 
showed that rank k=3 gave optimal clustering and that nonsmooth NMF performed best 
(Supplementary Material, Figure S4). The consensus matrix (average connectivity between 
metagenes and samples) obtained from using a NMF algorithm with random initialization 
after 1000 runs showed stable clustering of samples 54. The interaction network of top 
metagenes was assembled in Cytoscape using Reactome and STRING databases. 
STRING-based associations of further genes (first neighbors only) were considered with 
combined score ≥ 0.7 (high confidence). 
Data are available through Gene Expression Omnibus (GSE37584). 
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Figure Legend 
Figure 1. Schematic diagram of the IL7RA sequence showing the four SNPs used to stratify 
the Hamburg cohort into four common haplotypes. 
Figure 2. Haplotype dependent differences in IL-7RA mRNA and protein expression. (A) IL-
7RA mRNA expression from PBMCs of MS patients homozygous for haplotype 1-4 
was determined by q-PCR and is shown as ratio of membrane bound to soluble IL-
7RA mRNA isoform (sample size: Hap1: 14, Hap2: 11, Hap3: 17, Hap4: 4). (B) 
Differences in IL-7RA serum concentration were analyzed by sandwich ELISA. The 
sIL-7RA serum levels were analyzed in samples from 32 haplotype 1, 25 haplotype 2, 
30 haplotype 3, 4 haplotype 4 carrying homozygous and 11 heterozygous (for SNP 
rs6897932) MS patients. Results are presented as means ± s.d.; * P ≤ 0.05, ** P ≤ 
0.005 and *** P ≤ 0.001. 
Figure 3. Haplotype differences in IL-7RA surface expression. PBMCs of MS patients 
homozygous for either haplotype 1 (n=15) or haplotype 3 (n=14) were specifically 
stained for CD56bright cells and analyzed by flow cytometry. Results are presented as 
means ± s.d.; * P ≤ 0.05. 
Figure 4. Soluble IL-7RA is able to block IL-7 mediated signaling. IL-7 induced STAT5 
phosphorylation in CD4+ T lymphocytes was measured by flow cytometry in vitro. (A-
D) Histograms show the STAT5 phosphorylation in CD4+ T cells cultured in: 10 times 
concentrated HEK-cell supernatant, unstained unstimulated (dotted grey), 
unstimulated (dotted black), stimulated with 10-1000 pg/mL IL-7 (grey) and cultured in 
10 times concentrated supernatant of a HEK-cell line producing soluble IL-7RA 
stimulated with 10-1000 pg/mL IL-7 (black). Representative results from three 
independent experiments are shown as mean values ± s.d.; * P ≤ 0.05. 
Figure 5. (A) Multidimensional scaling of individual response values (gene expression level 
after stimulation versus gene expression level in unstimulated cells). A subset (830 
unique Ensembl gene IDs) corresponding to response values with low intra-group 
variability (lower third of median absolute difference per haplotype) was used. Color 
coding: haplotype 1, haplotype 2, and haplotype 3 are plotted as black, green, and 
red spheres, respectively. (B) Heatmap of CD4+ T cell responses to IL-7 stimulation 
for top-ranked metagenes. A subset of metagene-specific genes was selected from 
the top 10% contributing genes for each metagene and reconstructed values are 
shown (see Supplementary Material, Table S3 for raw data). Columns represent 
individual samples and rows the selected genes. Ordering of both samples and genes 
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was obtained from hierarchical clustering showing dendrograms on top and left side, 
respectively. Colorcoding uses row-wise scaling to emphasize between-haplotype 
differences. (C) Interaction network of top metagenes as obtained from Reactome 
and STRING. Genes based on Reactome association alone (red labels) and 
additional genes from input list found associated via STRING (yellow nodes). For 
clarity, only direct interactions between genes within the cytokine signaling in immune 
system network are shown. 
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Table 1. Allele and Genotype analysis of the four haplotype tagging SNPs  rs1494555, rs6897932, rs987107 and rs987106 in 484 multiple 
sclerosis patients and 310 HDs from Hamburg. 
SNP Allele Frequency in individuals with MS Frequency in controls Genotype 
Frequency in individuals 
with MS 
Frequency in 
controls 
p-value (dominat 
coding) 
Odds ratio (95% confidence 
interval) 
rs1494555 C 0.35 0.34 C/C 0.12 0.14   
T 0.65 0.66 C/T 0.45 0.40   
   T/T 0.43 0.46 0.38 0.88 (0.66 - 1.17) 
rs6897932 T 0.24 0.27 T/T 0.07 0.05   
C 0.76 0.73 C/T 0.33 0.43   
   C/C 0.60 0.52 0.03 1.38 (1.04 - 1.84) 
rs987107 T 0.30 0.26 T/T 0.10 0.06   
C 0.70 0.74 C/T 0.40 0.39   
   C/C 0.50 0.55 0.28 0.85 (0.64 - 1.13) 
rs987106 T 0.46 0.48 T/T 0.24 0.23   
A 0.54 0.52 A/T 0.45 0.50   
   A/A 0.31 0.27 0.30 1.19 (0.87 - 1.63) 
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 Table 2. Haplotype analysis of IL-7RA in 484 MS patients and 310 HDs from northern 
Germany using four adjacent SNPs that distinguish all common haplotypes 
 
 
 Haplotype Frequency 
Frequency in 
individuals with 
MS 
Frequency in 
controls p-value 
Haplotype 1 
(risk Hap) CCCT 0.34 0.35 0.34 0.78 
Haplotype 2 TCTA 0.28 0.30 0.26 0.09 
Haplotype 3 
(protective Hap) TTCA 0.25 0.24 0.27 0.20 
Haplotype 4 TCCT 0.12 0.12 0.14 0.24 
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Table 3. Gene expression differences in CD4+ T cells of MS individuals homozygous for 
one of three haplotypes (Hap1, Hap2, Hap3). Only genes whose expression levels 
varies maximally between haplotypes (top 0.1% divergent gene expression from F-test 
statistics, corresponding to p-value ≤ 1.8 E-3) and show the largest distances (top 1% of 
effect values) are shown. 
Ensembl ID Symbol p-value LogFC Hap1 vs Hap3 
LogFC Hap1 vs 
Hap2 
LogFC Hap3 vs 
Hap2 
ENSG00000202089 U6 snRNA 8.26E-04 -0.91 -2.38 -1.47 
ENSG00000212527 RN5S63 1.47E-04 0.99 -0.24 -1.23 
ENSG00000200796 U6 snRNA 5.39E-04 -0.50 -1.04 -0.54 
ENSG00000187172 BAGE2 1.43E-03 -0.64 0.34 0.97 
ENSG00000206826 U6 snRNA 2.30E-06 -0.10 -0.94 -0.84 
ENSG00000201813 U6 snRNA 9.35E-05 -0.17 -0.88 -0.71 
ENSG00000120322 PCDHB8 1.96E-04 -0.17 -0.87 -0.70 
ENSG00000201088 Y RNA 8.18E-04 -0.22 -0.84 -0.63 
ENSG00000125144 MT1G 7.88E-04 -0.09 0.70 0.79 
ENSG00000201065 U6 snRNA 7.17E-04 -0.25 -0.79 -0.53 
ENSG00000252574 RNU5B-6P 2.18E-05 -0.02 -0.70 -0.68 
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Table 4. Genes induced by stimulating isolated CD4+ T cells with IL-7. Top 1% of 
significantly regulated genes corresponding to adjusted p-value ≤ 1.6 E-5 sorted by 
absolute log fold change (10 entries each from strongly up- and down-regulated genes, 
respectively). Expression differences were calculated by combining samples according 
to stimulus (either unstimulated or stimulated) irrespectively of their haplotype 
assignment. 
Ensembl ID Symbol adj. p-value logFC 
ENSG00000114737 CISH 2.66E-11 2.69 
ENSG00000105810 CDK6 3.68E-10 2.61 
ENSG00000125384 PTGER2 3.36E-09 2.55 
ENSG00000137265 IRF4 3.02E-10 2.48 
ENSG00000171791 BCL2 8.51E-12 2.40 
ENSG00000079385 CEACAM1 2.45E-09 2.33 
ENSG00000067113 PPAP2A 1.25E-09 1.56 
ENSG00000157800 SLC37A3 3.36E-09 1.23 
ENSG00000074800 ENO1 3.03E-09 1.16 
ENSG00000171793 CTPS 3.36E-09 1.13 
ENSG00000123329 ARHGAP9 1.91E-06 -0.62 
ENSG00000165071 TMEM71 4.86E-06 -0.74 
ENSG00000137642 SORL1 2.66E-06 -0.83 
ENSG00000167261 DPEP2 3.04E-06 -0.87 
ENSG00000070731 ST6GALNAC2 7.64E-06 -0.87 
ENSG00000150054 MPP7 3.06E-06 -0.90 
ENSG00000106560 GIMAP2 7.11E-06 -0.91 
ENSG00000162894 FAIM3 8.73E-08 -1.12 
ENSG00000168685 IL7R 3.95E-07 -1.40 
ENSG00000176928 GCNT4 1.42E-06 -1.47 
 
 
